Table of Contents Table of Contents
Folie 1 Next Page
Information
Show Menu
Folie 1 Next Page

 


L0 - Wecome and Introduction - Guckenberger 		1
Slide Number 1 		1
Slide Number 2 		2
Slide Number 3 		3
Slide Number 4 		4
Slide Number 5 		5
Slide Number 6 		6
Slide Number 7 		7
Slide Number 8 		8
Slide Number 9 		9
Slide Number 10 		10
Slide Number 11 		11
Slide Number 12 		12
Slide Number 13 		13
Slide Number 14 		14
Slide Number 15 		15
Slide Number 16 		16
Slide Number 17 		17
Slide Number 18 		18
SBRT 2016_Course Book.pdf 		19
L1 - DV - Framebased-Frameless_partII_DV_2016 		19
L1 - KD - Definition_of_independent_lymph_node_regions_and_extranodal_lesions_in_C2_Version_1_1 		77
From frame-based Stereotaxy to frameless image-guidance a historical perspective 		77
History of Stereotactic Radiotherapy I 		78
History of stereotactic Radiotherapy II 		79
History of stereotactic Radiotherapy III 		80
Slide Number 5 		81
Slide Number 6 		82
Frame-based stereotactic Radiotherapy at a LINAC 		83
Frame-based Stereotactic Radiosurgery Positioning Accuracy 		84
Accuracy of non invasive Mask systems2D-2D image registration for verification set-up 		85
Accuracy of non invasive fixation systems3D-3D image registration for verification set-up 		86
Slide Number 11 		87
Slide Number 12 		88
Frames for fractionated extracranial /SBRT with a spine frame 		89
Extracranial Stereotactic Radiotherapy by Lax and Blomgreen in the early 90ies 		90
Slide Number 15 		91
Preliminaries for SBRT 		92
Slide Number 17 		93
Slide Number 18 		94
Slide Number 19 		95
New developments of the new machines opened the doors for high precision frame-less RT: 		96
Image guided frame-less Stereotactic Radiotherapy 		97
Image Guidance for SBRT 		98
Non invasive frame-based Stereotactic RTWork-Flow: Interval between planning in performance 		99
Indications increased for SBRT 		100
Slide Number 26 		101
ConclusionWhy is the step to frame-less Image Guided Stereotactic RT successful? 		102
Conclusion 		103
L2 - MH - Example I NSCLC 		104
Example I:SBRT for NSCLC stage I 		104
Slide Number 2 		105
Slide Number 3 		106
4D-CT skanning 		107
Slide Number 5 		108
Slide Number 6 		109
Slide Number 7 		110
Slide Number 8 		111
Slide Number 9 		112
Slide Number 10 		113
Slide Number 11 		114
Slide Number 12 		115
Slide Number 13 		116
L3 - MG - Case example SBRT - synchronous M+ NSCLC 		117
SBRT in synchronous metastatic NSCLC 		117
Slide Number 2 		118
Slide Number 3 		119
Slide Number 4 		120
Slide Number 5 		121
Slide Number 6 		122
Slide Number 7 		123
Slide Number 8 		124
Slide Number 9 		125
Slide Number 10 		126
Slide Number 11 		127
Slide Number 12 		128
Slide Number 13 		129
Slide Number 14 		130
Slide Number 15 		131
Slide Number 16 		132
L5 - MG - SBRT in the context of oncology - Guckenberger 		133
SBRT in the context of current developments in oncology 		133
Slide Number 2 		134
Slide Number 3 		135
Slide Number 4 		136
Slide Number 5 		137
Slide Number 6 		138
Slide Number 7 		139
Slide Number 8 		140
Slide Number 9 		141
Slide Number 10 		142
Slide Number 11 		143
Slide Number 12 		144
Slide Number 13 		145
Slide Number 14 		146
Slide Number 15 		147
Slide Number 16 		148
Slide Number 17 		149
Slide Number 18 		150
Slide Number 19 		151
Slide Number 20 		152
Slide Number 21 		153
Slide Number 22 		154
Slide Number 23 		155
Slide Number 24 		156
Slide Number 25 		157
Slide Number 26 		158
Slide Number 27 		159
Slide Number 28 		160
Slide Number 29 		161
Slide Number 30 		162
Slide Number 31 		163
Slide Number 32 		164
Slide Number 33 		165
Slide Number 34 		166
Slide Number 35 		167
Slide Number 36 		168
Slide Number 37 		169
L5 - MSH - MSHoogeman - New Technology - v1 		170
L6 - MH - SBRT_radiobiology 		204
Slide Number 1 		204
Do you believe that the linear-quadratic model should be used to convert SBRT doses to EQD2Gy doses? 		205
Slide Number 3 		206
Slide Number 4 		207
Slide Number 5 		208
Slide Number 6 		209
Slide Number 7 		210
Vascular effects 		211
Slide Number 9 		212
Slide Number 10 		213
Slide Number 11 		214
Immune effects 		215
Slide Number 13 		216
Slide Number 14 		217
Slide Number 15 		218
Slide Number 16 		219
Slide Number 17 		220
Slide Number 18 		221
Slide Number 19 		222
Slide Number 20 		223
Slide Number 21 		224
Slide Number 22 		225
30% 		226
Slide Number 24 		227
Slide Number 25 		228
Slide Number 26 		229
Slide Number 27 		230
Slide Number 28 		231
Slide Number 29 		232
Have you personally experienced an abscopal effect? 		233
Abscopal effects: They only occur with immune stimulating agents? 		234
Abscopal effects: They only occur with doses higher than 6 Gy? 		235
Slide Number 33 		236
Concommittant chemotherapy 		237
Slide Number 35 		238
Slide Number 36 		239
Slide Number 37 		240
Hypoxia 		241
Conclusions 		242
L7 - MG - Dose & fractionation in Lung SBRT - Guckenberger 		243
Slide Number 1 		243
Slide Number 2 		244
Slide Number 3 		245
Biology of Stereotactic Body radiotherapy 		246
Slide Number 5 		247
Slide Number 6 		248
Slide Number 7 		249
Slide Number 8 		250
Slide Number 9 		251
Slide Number 10 		252
Slide Number 11 		253
Slide Number 12 		254
Slide Number 13 		255
Slide Number 14 		256
Slide Number 15 		257
Slide Number 16 		258
Slide Number 17 		259
Slide Number 18 		260
Slide Number 19 		261
Slide Number 20 		262
Slide Number 21 		263
Slide Number 22 		264
Slide Number 23 		265
Slide Number 24 		266
Slide Number 25 		267
Slide Number 26 		268
Slide Number 27 		269
Slide Number 28 		270
L8 - MSH - MSHoogeman_Errors in SBRT_v3 		271
L9 - MSH - MSHoogeman_Margins in SBRT_v7 		310
Margins in SBRT 		310
Learning Objectives 		311
MARGIN CONCEPTS 		312
Why do we use margins? 		313
How large should the margin be? 		314
Categorization of Errors: a 2D Example 		315
Probability Density Function: Normal Distribution 		316
Systematic Errors Only (Msys = 2.5 S) 		317
Systematic Errors Only (Msys = 2.5 S) 		318
Random Errors Only: Mrand=0.7s 		319
Margin Recipe for Random Error 		320
Margin Calculation: Random Component 		321
Random Error and Minimum Dose Requirement 		322
Margin Recipe: Systematic Error and Random Errors 		323
How to Add Various Error Contributions? 		324
APPLICATION TO SRT AND SBRT 		325
Number of Fractions and Residual Systematic Error 		326
Effective Standard Deviation of the Errors 		327
Margin and Number of Fractions 		328
Including Error due to Respiratory Motion 		329
PRACTICAL EXAMPLES 		330
A Practical Example: SRT Case 		331
Which margin would you use for this treatment? 		332
A Practical Example: SRT Case 		333
Results SRT Example 		334
A Practical Example: SBRT Lung Case 		335
A Practical Example: SBRT Lung Case 		336
Margins SBRT Lung Case 		337
INTERNAL TARGET VOLUME 		338
ITV Concept in ICRU-62 Report 		339
Margin vs ITV for Perfect Inter-fraction Alignment 		340
Margin Recipe for Random Error 		341
Some Concluding Remarks 		342
References for Further Reading 		343
L10 - CH - 1 monday hurkmans management of targets brain and spine 2016 		344
Slide Number 1 		344
Slide Number 2 		345
Content 		346
Brain SBRT: required accuracy 		347
Frames 		348
Gamma knife 1968 		349
Gamma knife 2013 		350
Gamma knife 2015 		351
Masks: Literature 		352
Masks: Literature 		353
Bite blocks 		354
Slide Number 12 		355
After correction with IGRT 		356
IGRT practical implementation at CZE 		357
Mask QA study CZE: Translations 		358
Mask QA study CZE: Rotations 		359
Mask QA: experience with a new system 		360
Rotations in single isocentre treatments with multiple lesions 		361
Table assisted rotation correction 		362
Rotation correction with multiple lesions 		363
Rotation correction with multiple lesions 		364
Question 		365
Intra fraction motion: treatment time 		366
Intra fraction motion: treatment time 		367
Spine SBRT: Required accuracy 		368
Spine SBRT: Required accuracy 		369
Spine SBRT: Required accuracy MLC 		370
Spine SBRT: Required accuracy MLC 		371
Positioning for spine SBRT 		372
Positioning for spine SBRT 		373
Positioning for spine SBRT 		374
Imaging technology 		375
Slide Number 34 		376
Slide Number 35 		377
Brain SBRT: end-to-end accuracy at CZE 		378
The treatment chain 		379
The treatment chain: Measured uncertainties 		380
Take home message 		381
The bridge to Linac based RT: Volumes 		382
The bridge to Linac based RT: Dose 		383
The bridge to Linac based RT: Dose 		384
Dose prescription 		385
Prescription isodose vs modern linac RT 		386
Prescription isodose vs modern linac RT 		387
Prescription isodose vs modern linac RT 		388
Prescription isodose vs modern linac RT 		389
Prescription isodose vs modern linac RT 		390
Prescription isodose vs modern linac RT 		391
The bridge to Linac based RT: Dose 		392
Conclusion 		393
L10 - SL - Management of uncertainties in targets wo motion-Prostate_2016 		394
Management of uncertainties in targets w/o respiration motionProstateStephanie LangUniversity Hospital Zürich 		394
Slide Number 2 		395
Contouring uncertainty 		396
Contouring uncertainty 		397
Contouring uncertainty 		398
Definition of the tumor lesion 		399
Definition of the tumor lesion 		400
MRI to CT Matching 		401
Slide Number 9 		402
Slide Number 10 		403
Slide Number 11 		404
Slide Number 12 		405
Slide Number 13 		406
Slide Number 14 		407
What kind of Image guidance would you use for SBRT prostate cancer? 		408
Slide Number 16 		409
Slide Number 17 		410
Slide Number 18 		411
Slide Number 19 		412
Slide Number 20 		413
Slide Number 21 		414
Slide Number 22 		415
Slide Number 23 		416
Slide Number 24 		417
Slide Number 25 		418
Slide Number 26 		419
Slide Number 27 		420
Remaining uncertainty - deformations 		421
Slide Number 30 		422
During a prostate SBRT treatment fraction, how often does on average the prostate move more than 2mm? 		423
Slide Number 32 		424
Slide Number 33 		425
Slide Number 34 		426
Slide Number 35 		427
Slide Number 36 		428
Slide Number 37 		429
Slide Number 38 		430
Slide Number 39 		431
Slide Number 40 		432
Slide Number 41 		433
Slide Number 42 		434
Slide Number 43 		435
Recommeded Literature 		436
Slide Number 45 		437
L11 - DV - ManagementRespirationInducedMotion_PartII_DV_2016 		438
L11 - MSH - MSHoogeman_RespiratoryMotionUncertainties_v2 		556
L12 - CH - 2 monday hurkmans planning and evaluation 2016 		606
Slide Number 1 		606
First a tough one.. 		607
First SBRT: Gammaknife 		608
Historical dose prescription: on the xx% isodose 		609
Dose prescription beyond conformal:ICRU 		610
Historical vs ICRU vs SBRT 		611
Be careful clinicians – physicists don’t know what they do! 		612
Be careful physicists – clinicians also don’t know! 		613
Harmonisation of dose prescription and dose reporting nomenclature is needed!Dose in relation to volume 		614
Dose in relation to volume: Target 		615
Dose in relation to volume: OARs 		616
Dose in relation to volume: OARs 		617
Dose in relation to volume: OARs 		618
Chest wall /Ribs dose effects 		619
Chest wall /Ribs dose effects 		620
Chest wall /Ribs dose effects 		621
Chest wall /Ribs dose effects 		622
Treatment planning 		623
SBRT lung in The Netherlands 2008 		624
SBRT lung in The Netherlands 2013 		625
Technique flavours 		626
Why dosimetric strategies work 		627
Why it works best in lung 		628
Breathing margins: margin recipe 		629
Bold statement / Take home message 		630
Bold statement / Take home message 		631
Dose calculation algorithms 		632
Influence on dose distribution 		633
Actual delivered dose – 26 pts 		634
Dose criteria – low-dose conformity 		635
Dose criteria – lung dose 		636
Dose calculation 		637
Prescription dose 		638
Algorithm dependent criteria: ROSEL 		639
Revised RTOG criteria: Xiao et al 		640
It is clinically relevant! 		641
What is true? 		642
Planning technique 		643
Planning technique 		644
Planning technique 		645
Delivery time 		646
Delivery time - FFF 		647
Conclusions 		648
L12 - SL - Treatment planning_SpineLiverProstate_2016 		649
SBRT treatment planning Liver, Spine and ProstateStephanie LangUniversity Hospital Zürich 		649
Slide Number 2 		650
In your department, do you perform 		651
SBRT liver treatment planning 		652
Slide Number 5 		653
Slide Number 6 		654
Slide Number 7 		655
Slide Number 8 		656
Slide Number 9 		657
Slide Number 10 		658
Slide Number 11 		659
Slide Number 12 		660
Treatment planning for liver cancer 		661
3D conformal treatment planning 		662
3D conformal treatment planning 		663
3D conformal treatment planning 		664
3D conformal treatment planning 		665
Coplanar versus non-coplanar 		666
Do we need VMAT? 		667
VMAT optimisation 		668
VMAT – how to achieve the inhomogeneity 		669
VMAT – how to achieve the inhomogeneity 		670
VMAT - Optimisation help structures 		671
VMAT - Optimisation help structures 		672
VMAT – dose distribution 		673
VMAT – dose distribution 		674
Plan evaluation 		675
Plan evaluation 		676
Plan evaluation 		677
Slide Number 30 		678
Slide Number 31 		679
How large is the interplay effect for a VMAT SBRT liver treatment fraction (2 arcs, 13.5Gy, 65% isodose)? 		680
Slide Number 33 		681
Slide Number 34 		682
SBRT spine treatment planning 		683
Different concepts 		684
SBRT of spine tumors 		685
SBRT of spine tumors 		686
SBRT of spine tumors 		687
SBRT of spine tumors 		688
SBRT of spine tumors 		689
SBRT spine – integrated boost concept 		690
SBRT spine – integrated boost concept 		691
SBRT spine – integrated boost concept 		692
SBRT spine – integrated boost concept 		693
SBRT spine – integrated boost concept 		694
SBRT prostate treatment planning 		695
Different concepts 		696
SBRT Prostate 		697
SBRT Prostate - OAR 		698
FFF beams – any advantage? 		699
Slide Number 52 		700
SBRT treatments 		701
Slide Number 54 		702
Slide Number 55 		703
Slide Number 56 		704
L13 - CH - 3 monday hurkmans QA and safety in SBRT 2016 		705
Slide Number 1 		705
Content - objectives 		706
Do Accidents Happen? 		707
Exeter, UK, 1988 		708
Outcome 		709
North Staffordshire Royal Infirmary, 1982-1991 		710
North Staffordshire Royal Infirmary, 1982-1991 		711
Glasgow, Scotland 2005 		712
Except for… 		713
Lessons 		714
Jan 2010 		715
Energy and Commerce - Subcommittee on Health held a hearing entitled "Medical Radiation: An Overview of the Issues" on Friday, February 26, 2010 		716
Let’s have the story 		717
What happened? 		718
What happened? 		719
What happened? 		720
What happened? 		721
What happened? 		722
What happened? 		723
Discovery of accident 		724
Lessons: 		725
Recently… New identical Linac… 		726
Recently… New identical Linac… 		727
Recently… New identical Linac… 		728
Recently… New identical Linac… 		729
Take home messages 		730
Reason’s Swiss Cheese Model of Failure Propagation 		731
Radiotherapy safety layers 		732
Which QA tools are effective? 		733
Which combination of QA tools are effective? 		734
Stress and workload 		735
Q:What is the main cause of errors? 		736
Failure Modes and Effects Analysis 		737
From flow charts 		738
To failure modes using Fault Tree Analysis 		739
And ranking risks using RPN 		740
To reducing risks 		741
Take home messages 		742
Acknowledgements 		743
L14 - MG - Evidence-based SBRT for stage I NSCLC - Guckenberger 		744
Slide Number 1 		744
Slide Number 2 		745
Slide Number 3 		746
Slide Number 4 		747
Slide Number 6 		748
Slide Number 7 		749
Slide Number 8 		750
Slide Number 9 		751
Slide Number 10 		752
Slide Number 11 		753
Slide Number 12 		754
Slide Number 13 		755
Slide Number 14 		756
Slide Number 15 		757
Slide Number 16 		758
Slide Number 17 		759
Slide Number 18 		760
Slide Number 19 		761
Slide Number 20 		762
Slide Number 21 		763
Slide Number 22 		764
Slide Number 23 		765
Slide Number 24 		766
Slide Number 25 		767
Slide Number 26 		768
Slide Number 27 		769
Slide Number 28 		770
Slide Number 29 		771
Slide Number 30 		772
Slide Number 31 		773
Slide Number 32 		774
Slide Number 33 		775
Slide Number 34 		776
Slide Number 35 		777
Slide Number 36 		778
Slide Number 37 		779
Slide Number 38 		780
Slide Number 39 		781
Slide Number 40 		782
Slide Number 41 		783
Slide Number 42 		784
Slide Number 43 		785
Slide Number 44 		786
Slide Number 45 		787
Slide Number 46 		788
Slide Number 47 		789
Slide Number 48 		790
Slide Number 49 		791
Slide Number 50 		792
Slide Number 51 		793
Slide Number 52 		794
Slide Number 53 		795
Slide Number 54 		796
Slide Number 55 		797
Slide Number 56 		798
Slide Number 57 		799
Slide Number 58 		800
L15 - ESTRO ACROP Guidelines SBRT NSCLC - Guckenberger 		801
Slide Number 1 		801
Slide Number 2 		802
Slide Number 3 		803
Slide Number 4 		804
Slide Number 5 		805
Slide Number 6 		806
Slide Number 7 		807
Slide Number 8 		808
Slide Number 9 		809
Slide Number 10 		810
Slide Number 11 		811
Slide Number 12 		812
Slide Number 13 		813
Slide Number 14 		814
Slide Number 15 		815
Slide Number 16 		816
Slide Number 17 		817
Slide Number 18 		818
Slide Number 19 		819
Slide Number 20 		820
Slide Number 21 		821
Slide Number 22 		822
Slide Number 23 		823
Slide Number 24 		824
Slide Number 25 		825
Slide Number 26 		826
Slide Number 27 		827
Slide Number 28 		828
Slide Number 29 		829
Slide Number 30 		830
Slide Number 31 		831
Slide Number 32 		832
Slide Number 33 		833
L16 - CH - 4 tuesday hurkmans practical sessions 2016 		834
Slide Number 1 		834
Content 		835
Clinical casus: intra-fraction motion 		836
Slide Number 4 		837
Slide Number 5 		838
Slide Number 6 		839
Slide Number 7 		840
Slide Number 8 		841
Slide Number 9 		842
Slide Number 10 		843
Original plan 		844
Original plan with shift 		845
New plan with 3mm extra margin 		846
New plan with shift: robust? 		847
Vmat CVDR option 		848
Online 4D CBCT 		849
Online 4D CBCT 		850
Slide Number 22 		851
Slide Number 23 		852
Intra fraction stability CZE 		853
Intra fraction stability CZE 		854
Patient specific dosimetry CZE 		855
Gamma analysis 		856
Gamma results 		857
4D Dosimetry QA 		858
4D Dosimetry QA 		859
Gamma results brain VMAT 		860
QA VMAT – 3% 3mm 		861
QA VMAT – 2% 2mm 		862
IMRT vs VMAT – irradiation time 		863
EORTC Lungtech protocol 		864
Lungtech: Dose to bronchial tree 		865
Dutch phase III trial: WBRT vs SBRT 4-10 leasions 		866
Dutch consensus guideline 2014 on brain metastases treatment 		867
Dutch consensus guideline 2014: Prescribing 		868
Dutch consensus guideline 2014: Reporting 		869
L17 - MG - SBRT for pancreatic Cancer - Guckenberger 		870
Slide Number 1 		870
Slide Number 2 		871
Slide Number 3 		872
Slide Number 4 		873
Slide Number 5 		874
Slide Number 6 		875
Slide Number 7 		876
Slide Number 8 		877
Slide Number 9 		878
Slide Number 10 		879
Slide Number 11 		880
Slide Number 12 		881
Slide Number 13 		882
Slide Number 14 		883
Slide Number 15 		884
Slide Number 16 		885
Slide Number 17 		886
Slide Number 18 		887
Slide Number 19 		888
Slide Number 20 		889
L17 - MG - SBRT for prostate Cancer - Guckenberger 		890
SBRT forProstate Cancer 		890
Slide Number 2 		891
Slide Number 3 		892
Slide Number 4 		893
Slide Number 5 		894
Slide Number 6 		895
Slide Number 7 		896
Slide Number 8 		897
Slide Number 9 		898
Slide Number 10 		899
Slide Number 11 		900
Slide Number 12 		901
Slide Number 13 		902
Slide Number 14 		903
Slide Number 15 		904
Slide Number 16 		905
Slide Number 17 		906
Slide Number 18 		907
Slide Number 19 		908
Slide Number 20 		909
Slide Number 21 		910
Slide Number 22 		911
Slide Number 23 		912
Slide Number 24 		913
Slide Number 25 		914
Slide Number 26 		915
L18 - MG - Primary SBRT for vertabral metastases - Guckenberger 		916
Stereotactic body radiotherapy for vertebral metastases 		916
Slide Number 2 		917
Slide Number 3 		918
Slide Number 4 		919
Slide Number 5 		920
Slide Number 6 		921
Slide Number 7 		922
Slide Number 8 		923
Slide Number 9 		924
Slide Number 10 		925
Slide Number 11 		926
Slide Number 12 		927
Slide Number 13 		928
Slide Number 14 		929
Slide Number 15 		930
Slide Number 16 		931
Slide Number 17 		932
Slide Number 18 		933
L18 - MG - Reirradiation SBRT for vertebral metastases- Guckenberger 		934
Stereotactic body radiotherapy for vertebral metastases 		934
Slide Number 2 		935
Slide Number 3 		936
Slide Number 4 		937
Slide Number 5 		938
Slide Number 6 		939
Slide Number 7 		940
Slide Number 8 		941
Slide Number 9 		942
Slide Number 10 		943
Slide Number 11 		944
Slide Number 12 		945
Slide Number 13 		946
Slide Number 14 		947
Slide Number 15 		948
Slide Number 16 		949
Slide Number 17 		950
Slide Number 18 		951
Slide Number 19 		952
Slide Number 20 		953
Slide Number 21 		954
Slide Number 22 		955
Slide Number 23 		956
L19 - AMR - for box 2016 Mnd practice of liver SBRT 		957
Slide Number 1 		957
LEARNING OBJECTIVES 		958
INDICATIONS LIVER METASTASES 		959
IMMOBILIZATION 		960
RESPIRATORY MANAGEMENT 		961
BREATHING MANAGEMENT 		962
FIDUCIAL IMPLANT 		963
COMPLICATIONS 		964
PURPOSE FIDUCIAL IMPLANT 		965
IMAGING FOR DELINEATION 		966
CT PLANNING 		967
Margins and IGRT Solutions 		968
Margins at Erasmus MC 		969
Margins at Erasmus MC using CK 		970
Distribution of Margins Used Clinically 		971
Solutions for IGRT 		972
Solution for IGRT 		973
LOCAL CONTROL LIVER METASTASES 		974
CONSTRAINTS 		975
MESSAGE TO TAKE HOME 		976
L20 - AMR - for box SBRT for primary liver cancer 		977
Slide Number 1 		977
LEARNING OBJECTIVES 		978
PRIMARY LIVER TUMORS 		979
IS THERE A ROLE FOR SBRT IN HCC? 		980
HCC TREATED RADICALLY 		981
HCC TREATED RADICALLY 		982
SBRT vs. RFA 		983
TACE COMBINED WITH RT 		984
SBRT COMBINED WITH SORAFENIB 		985
HCC TREATED PRE-TRASPLANT 		986
HCC TREATED PRE-TRASPLANT 		987
IS THERE A ROLE FOR SBRT IN CCA? 		988
CCA TREATED RADICALLY 		989
CCA TREATED RADICALLY 		990
CCA TREATED PRE-TRANSPLANT 		991
RELATION DOSE/LOCAL CONTROL 		992
SUSCEPTIBILITY HEPATIC TOXICITY 		993
HEPATIC TOXICITY SBRT STUDIES 		994
PREDICTORS BILIARY TRACT TOXICITY 		995
DOSE VOLUME RECOMMENDATIONS 		996
MESSAGE TO TAKE HOME 		997
L21 - KD - Arbeitsprogramm 		998
OligometastasesRational for stereotactic radiotherapy 		998
Questions 		999
Questions 		1000
Questions 		1001
Questions 		1002
Questions 		1003
Questions 		1004
One Definition of Oligometastases 		1005
Slide Number 9 		1006
Slide Number 10 		1007
Oligometastases and Oligo-RecurrenceOligo-Progression 		1008
Slide Number 12 		1009
Clinical evidenceSurgery and ablation for CRC oligo-metastases 		1010
Slide Number 14 		1011
Prospective studies with oligometastases of Lung treated with SBRTOligo metastases: new paradigm and options for radiotherapy 		1012
Slide Number 16 		1013
Prospective studies with oligometastases of the liver treated with SBRTOligo metastases: new paradigm and options for radiotherapy 		1014
Slide Number 18 		1015
Slide Number 19 		1016
Slide Number 20 		1017
Who is the right patient forSBRT 		1018
Patient selection 		1019
Lung Metastases Eligibility Criteria 		1020
Liver Metastases Eligibility Criteria 		1021
Case 		1022
What would you advice? 		1023
Slide Number 27 		1024
Factors who might influence local control(survival s; local control c) 		1025
Drugs, SBRT and Oligometastases 		1026
Conclusion 		1027
L21 - MH - oligometastases II_MH 		1028
Slide Number 1 		1028
Clinical evidenceSurgery and ablation for CRC oligo-metastases 		1029
Lung metastases 		1030
Slide Number 4 		1031
Slide Number 5 		1032
Liver metastases 		1033
Slide Number 7 		1034
Slide Number 8 		1035
Lymph node metastases 		1036
Slide Number 10 		1037
Slide Number 11 		1038
Adrenal metastases 		1039
Slide Number 13 		1040
Metastatic colorectal cancer 		1041
Slide Number 15 		1042
Slide Number 16 		1043
Slide Number 17 		1044
Overall survival after SBRT for mCRC 		1045
Prognostic factors related to survival after SBRT for mCRC 		1046
SBRT and chemotherapy for mCRC 		1047
Overall survival after SBRT for mCRCMultivariate analysis 		1048
Slide Number 22 		1049
Histology versus local failure 		1050
Radiation dose and local control 		1051
Radiation dose and local control in mCRC 		1052
Slide Number 26 		1053
Metastatic prostate cancer 		1054
Slide Number 28 		1055
Slide Number 29 		1056
Slide Number 30 		1057
Prognostic factors 		1058
Slide Number 32 		1059
Slide Number 33 		1060
Slide Number 34 		1061
Slide Number 35 		1062
Treatment of cancer in a Multidisciplinary Team 		1063
Slide Number 37 		1064
L22 - LB - ESTRO course, practice of SBRT Lineke [for sharing] 		1065
Practice of SBRT : RTT perspective 		1065
Slide Number 2 		1066
RTTs role in treatment 		1067
Patient positioning (Lung, Spine, Liver) 		1068
Patient positioning (brain, spine (above T4)) 		1069
IGRT-options in your department 		1070
IGRT-protocols 		1071
IGRT-protocols 		1072
Slide Number 9 		1073
Orthogonal kV-images 		1074
CT, normal spine case 		1075
CBCT, normal spine case 		1076
Slide Number 13 		1077
IGRT-protocols 		1078
Slide Number 15 		1079
Post-treatment CBCT, SBRT lung 		1080
Motion management (1) 		1081
Motion management (2) 		1082
Slide Number 19 		1083
Slide Number 20 		1084
Expiration Breathhold: why & where? 		1085
Imaging:FreebreathingvsExpirationBreathhold 		1086
Intrafraction monitoring devices 		1087
Intrafraction monitoring 		1088
RPM-system 		1089
ExacTrac (ET) 		1090
ET Extra-cranial positioning 		1091
ET infrared positioning 		1092
Monitoring ExacTrac markers 		1093
Stability based on ExacTrac 		1094
Auto Beam Hold package 		1095
Auto detection and Beam Hold 		1096
Triggered Imaging 		1097
1098
Offline intrafraction monitoring 		1099
Results intrafraction monitoring 		1100
Acknowledgments 		1101
Questions? 		1102
L22 - MSH - MSHoogeman - QA for Imaging - v1 		1103
L23 - KD - Starting a SRT Program 		1136
Starting a SRT Program for Brain and Body:Clinicians perspective 		1136
Motivation for SRS / SBRT 		1137
Outline 		1138
Questions you have to answer when you decide to implement a stereotactic program 		1139
Referral 		1140
To do`s: planning of program 		1141
Protocol generation 		1142
Team building 		1143
Staffing-Building a SRT teamTraining 		1144
Visit an experienced center 		1145
Staffing-Building a SRT Team 		1146
Slide Number 12 		1147
Equipment demands 		1148
Equipment demands 		1149
Equipment demands 		1150
Do we have to treat every patient in a study ? 		1151
Slide Number 17 		1152
Follow-up 		1153
Follow-up 		1154
Reimbursement 		1155
Slide Number 21 		1156
L23 - LB - ESTRO course, starting up Lineke [for sharing] 		1157
Starting your SBRT program: RTT perspective 		1157
Treatment 		1158
Interdisciplinary team 		1159
Slide Number 5 		1160
Training scheme 		1161
RTTs role 		1162
RTTs role 		1163
RTTs role 		1164
RTTs role 		1165
Who is essential on the linacby starting up a new tumorside? 		1166
Who is essential on the linac when you have experience with the SBRT treatment? 		1167
Treatment 		1168
Slide Number 14 		1169
Treatment 		1170
Slide Number 16 		1171
Post-treatment CBCT, SBRT lung 		1172
Motion management (1) 		1173
Intrafraction monitoring 		1174
Stability based on ExacTrac 		1175
Common remarks 		1176
Some key notes 		1177
Questions? 		1178
L23 - MSH - MSHoogeman_Starting a SBRT program_v2 		1179
L24 - CH - 5 thursdaywhat can go wrong in SBRT 2016 		1202
Slide Number 1 		1202
Content 		1203
Example: prescription change 		1204
Unexpected shifts 		1205
Unexpected shifts: Dose shift 		1206
Unexpected shifts: Dose shift 		1207
Wrong CT for matching with CBCT 		1208
Wrong CT for matching: 4D-CT 		1209
Wrong CT for matching: re-plan 		1210
Too low dose due to proximity of OAR 		1211
Too low dose due to proximity of OAR 		1212
Too low dose due to proximity of OAR 		1213
+ Wrong OAR auto-delineation.. 		1214
Too low dose due to proximity of OAR? 		1215
Too small lesions to detect on CBCT 		1216
Too small lesions to detect on CBCT 		1217
Too small lesions to detect on CBCT 		1218
Too small lesions to detect on CBCT 		1219
Too small lesions…for dose calculation? 		1220
Software upgrades: QA software 		1221
What is most important to keep your SBRT program safe? 		1222
Take home message 		1223
Take home message / acknowledgements 		1224
 FlippingBook